Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CBIO Stock 12 Month Forecast
Average Price Target
$28.20
▲(157.06% Upside)
| Highest Price Target$35.00 | Average Price Target$28.20 | Lowest Price Target$22.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$22
Buy
100.55%
Upside
Reiterated
01/05/26
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunitys: This morning, CBIO announced that the FDA cleared its IND for CR-001 and that partner Kelun-Biotech received IND approval for China's NMPA. Recall that last month, CBIO announced a strategic collaboraon with K elun for CR-001 and CR-003 (see our previous Note), where Kelun granted CBIO exclusive rights to research, develop, and commercialize and all markets outside Greater China, and CBIO granted Kelun exclusive rights to research, develop, and commercialize CR-001 in Greater China. The global Phase 1/2 ASCEND evaluang CR-001 is expected to enroll up to 290 paen ts in both 1L and 2L+ sengs across eight tumor types, including NSCLC, HCC, CRC, gastric, biliary and gyn tumors, with POC data including safety, PK/PD, and early an- tumor acvity e xpected in 1Q 2027 (see image below for general details & design).
Wedbush
$27
Buy
146.13%
Upside
Initiated
12/18/25
Jefferies
$35
Buy
219.05%
Upside
Reiterated
12/05/25
Stifel Nicolaus
$28→$32
Buy
191.70%
Upside
Reiterated
12/04/25
H.C. Wainwright
$25
Buy
127.89%
Upside
Reiterated
11/10/25
TD Cowen
Buy
―
Reiterated
11/06/25
Cantor Fitzgerald
Buy
―
Initiated
03/21/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$22
Buy
100.55%
Upside
Reiterated
01/05/26
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunitys: This morning, CBIO announced that the FDA cleared its IND for CR-001 and that partner Kelun-Biotech received IND approval for China's NMPA. Recall that last month, CBIO announced a strategic collaboraon with K elun for CR-001 and CR-003 (see our previous Note), where Kelun granted CBIO exclusive rights to research, develop, and commercialize and all markets outside Greater China, and CBIO granted Kelun exclusive rights to research, develop, and commercialize CR-001 in Greater China. The global Phase 1/2 ASCEND evaluang CR-001 is expected to enroll up to 290 paen ts in both 1L and 2L+ sengs across eight tumor types, including NSCLC, HCC, CRC, gastric, biliary and gyn tumors, with POC data including safety, PK/PD, and early an- tumor acvity e xpected in 1Q 2027 (see image below for general details & design).
Wedbush
$27
Buy
146.13%
Upside
Initiated
12/18/25
Jefferies
$35
Buy
219.05%
Upside
Reiterated
12/05/25
Stifel Nicolaus
$28→$32
Buy
191.70%
Upside
Reiterated
12/04/25
H.C. Wainwright
$25
Buy
127.89%
Upside
Reiterated
11/10/25
TD Cowen
Buy
―
Reiterated
11/06/25
Cantor Fitzgerald
Buy
―
Initiated
03/21/25
Best Analysts Covering Crescent Biopharma
3 Months
xxx
Success Rate
5/13 ratings generated profit
Average Return
-0.13%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of -0.13% per trade.
1 Year
Success Rate
4/13 ratings generated profit
Average Return
-16.58%
reiterated a buy rating last month
Copying Stephen Willey's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -16.58% per trade.
2 Years
xxx
Success Rate
1/13 ratings generated profit
Average Return
-31.88%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.69% of your transactions generating a profit, with an average return of -31.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CBIO Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Nov 25
Dec 25
Jan 26
Strong Buy
5
10
9
11
7
Buy
2
2
2
1
1
Hold
0
0
0
0
0
Sell
2
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
12
11
12
8
Each month's total comprises the sum of three months' worth of ratings.
CBIO Financial Forecast
CBIO Stock Forecast FAQ
What is CBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Crescent Biopharma’s 12-month average price target is 28.20.
What is CBIO’s upside potential, based on the analysts’ average price target?
Crescent Biopharma has 157.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CBIO a Buy, Sell or Hold?
Crescent Biopharma has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Crescent Biopharma’s price target?
The average price target for Crescent Biopharma is 28.20. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $22.00. The average price target represents 157.06% Increase from the current price of $10.97.
The highest analyst price target is $35.00 ,the lowest forecast is $22.00. The average price target represents 157.06% Increase from the current price of $10.97.
What do analysts say about Crescent Biopharma?
Crescent Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of CBIO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.